الفهرس 
Introduction & Aim of the workOnly 14 pages are availabe for public view
 |  | from | 196 |  |  |
| | | from | 196 | | |
Abstract
Alopecia, or hair loss, can be mainly subdivided into non-scarring, non-cicatricial or reversible and scarring, cicatricial or irreversible forms.
Many medications were marketed that, however modestly and inconsistently, did stimulate hair growth. These, accidentally discovered, first-generation hair growth medications - minoxidil, finasteride and latanoprost - are landmarks because they inspired us that we can affect hair growth and regeneration medically. However, they fail to regenerate new HFs in bald scalp.
The goal of “regenerative medicine” is to get living, functional tissues which restore missing or damaged organ function following disease, trauma, congenital abnormality or senescence. The chief obstacle in regenerative medicine is the recomposition of completely highly organized and functional tissues from dissociated cells that have been cultured using defined tissue culture conditions. Hence, the use of cell-based therapies to compensate for skin or hair loss may provide an alternative source for regenerative therapies.
The potential candidate HFBSCs markers include CD200; ITGA6; ITGB1, transcription factor P63, KRT19, and KRT15.
ESCs are characterized by an endless proliferative potential and extensive differentiation capacity. They are considered as an alternative source for regenerative medicine with a crucial role in the management of many diseases. Unfortunately, the use of ESCs clinically is currently clouded by serious moral and biological issues owing to their origin from embryos and possibility for immunological rejection, respectively.